Founded more than 115 years ago by a group of volunteers dedicated to ending the lung health threat at the time — tuberculosis — today, the American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease.

Established in 2000, the Foundation for Sarcoidosis Research (FSR), is the leading international non-profit organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients through research, education and support.

Since launching as a spin-out from the University of Oxford, Brainomix has developed award-winning, AI-powered imaging biomarkers and software solutions that assist physicians around the world in improving both diagnosis and treatment decisions.

The Oxford, UK-headquartered medical software company first gained attention with its e-Stroke platform, a CE-marked collection of tools that use advanced AI algorithms to provide doctors with real-time interpretation of brain scans that can help guide treatment and transfer decisions for stroke patients. Considered the world’s most comprehensive stroke imaging solution, it has been widely adopted across multiple healthcare systems worldwide, in more than 30 countries.

Building on this legacy and success, Brainomix has since expanded beyond stroke into new areas where there are similar unmet needs and opportunities to improve diagnosis and treatment. These include cancer and lung fibrosis, notably the assessment of interstitial lung diseases (ILDs).
​
We spoke with OSIC Board Member Dr. George Harston – Chief Medical & Innovation Officer at Brainomix and a practicing Consultant Physician at the John Radcliffe Hospital in Oxford, England – about the company’s new e-ILD solution, and the value of collaborating with OSIC and its members.

Founded in 2005, FLUIDDA provides respiratory solutions for better patient care. As a major player in the field of Quantitative Pulmonary CT, FLUIDDA leads the pack with its proprietary Functional Respiratory Imaging (FRI) technology. This technique combines HRCT scans and Computational Fluid Dynamics technology, which offers vast improvements by making clinical trials shorter, faster, and more cost effective.
 
FRI also helps patients and healthcare providers in offering a unique entry point in personalized medicine, by optimizing diagnosis, monitoring disease progression, and the effects of therapy. FLUIDDA’s goal is to improve the lives of people suffering from respiratory diseases by optimizing treatment pathways, reducing healthcare costs, and limiting the go-to-market time of respiratory drugs, pulmonology medical devices, and therapies.

This passion for innovation is what drove FLUIDDA to become a founding member of OSIC. From the start, FLUIDDA has shared its expertise and learnings with us, and has been a key influence in helping shape our mission and drive our strategic direction.

We spoke with FLUIDDA CEO Jan De Backer, who also serves as a member of our board of directors, about what first drew him to OSIC, the unique perspective that FLUIDDA brings to our organization, and where he sees OSIC five years down the line. Following is an excerpt from our conversation.